A clinical study to compare giredestrant with fulvestrant, both combined with a targeted therapy (CDK4/6 inhibitor) in people with ER-positive, HER2-negative breast cancer that has come back after adjuvant hormone therapy

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  • Cancer
  • Breast Cancer
  • Breast Cancer HER-2 Negative
  • Estrogen Receptor (ER)-Positive
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Recruiting

This trial runs in
Cities
  • ABD
  • Adelaide
  • Alvarado
  • Annapolis
  • Antwerpen
  • Atlanta
  • Austin
  • Avellino
  • Avignon
  • Badalona
  • Bahia
  • Barcelona
  • Barrie
  • bei-jing-shi
  • Besançon
  • Bogotá
  • Bologna
  • Brescia
  • Brindisi
  • Bruxelles
  • Buenos Aires
  • Caen
  • California
  • cascina-perseghetto
  • Ceará
  • Chang Wat Chiang Mai
  • chang-chun-shi
  • chang-sha-shi
  • cheng-du-shi
  • chong-qing-shi
  • Ciudad de Guatemala
  • Coimbra
  • Córdoba
  • Daegu
  • Dallas
  • Denver
  • east-brunswick
  • El Palmar
  • Espírito Santo
  • Frederick
  • frenchs-forest
  • friuli-venezia-giulia
  • fu-zhou-shi
  • Fuzhou
  • Gdynia
  • Geelong
  • Gent
  • Germantown
  • Goiás
  • guang-zhou-shi
  • guatemala-department
  • hang-zhou-shi
  • Harbin
  • Hong Kong Island
  • hsinchu-city
  • Huelva
  • Jacksonville
  • Jaén
  • Jerez de la Frontera
  • Jerusalem
  • Ji Nan Shi
  • Jinan
  • Kielce
  • Kingswood
  • Konin
  • Kunming
  • Köln
  • La Rioja
  • La Rochelle
  • Lancaster
  • Leuven
  • Lisboa
  • Lisbon
  • Los Angeles
  • luik
  • Luo Yang Shi
  • Lyon
  • Lévis
  • Madrid
  • Medford
  • Meldola
  • Milano
  • Miskolc
  • Montería
  • Montpellier
  • Montréal
  • Namur
  • nan-ning-shi
  • Newport Beach
  • North Sydney
  • Novara
  • Oshawa
  • Padova
  • Palmerston North
  • Parma
  • Pernambuco
  • Petah Tikva
  • Porto
  • Pozuelo de Alarcón
  • Providencia
  • Puerto Montt
  • Pune
  • Quetzaltenango
  • Québec
  • Ramat Gan
  • Reims
  • Rio Grande do Sul
  • Roma
  • Rosario
  • saguenay
  • Saint Albans
  • Saint-Jérôme
  • San José
  • San Juan
  • sant-andreu-de-la-barca
  • Santa Fe
  • Santiago
  • Scarborough
  • selcetta
  • Seongnam-si
  • Seoul
  • Sevilla
  • Shanghai
  • sicilia
  • siedlce
  • Sioux Falls
  • Sippy Downs
  • South Brisbane
  • Szczecin
  • São Paulo
  • tai-zhou-shi
  • Taichung City
  • Taipei City
  • Taiyuan
  • tambon-kho-hong
  • Tel Aviv-Yafo
  • tian-jin-shi
  • Toronto
  • Torrance
  • Toulouse
  • Udine
  • Ulsan
  • valledupar
  • València
  • Vigo
  • Vila Nova de Gaia
  • Villejuif
  • warrnambool
  • Washington
  • wu-han-shi
  • Wuhan
  • Xi'an
  • xi-an-shi
  • xu-zhou-shi
  • York
  • zheng-zhou-shi
  • Ürümqi
  • Łódź
Trial Identifier:

NCT06065748 2022-502980-39-00 CO44657

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT06065748,CO44657,2022-502980-39-00 Trial Identifier
      All Gender
      ≥18 Years Age
      No Healthy Volunteers

      1. Why is the pionERA BC clinical study needed?

      The body naturally produces oestrogen, a hormone which stimulates breast cancer cells that have the oestrogen receptor (known as ‘ER-positive breast cancer’) to grow. Standard treatment for ER-positive breast cancer that has not grown beyond the breast (known as ‘early’ breast cancer) includes surgery, chemotherapy and/or radiotherapy, followed by hormone therapy – known as ‘adjuvant therapy’.

      In some people, adjuvant therapy can stop working (known as ‘treatment resistance’) due to changes (mutations) in the ER, and ER-positive breast cancer can come back (known as a ‘relapse’). The standard approved treatments for people who have cancer that relapses during or shortly after adjuvant treatment is a type of medicine called a ‘cyclin-dependent kinase 4 or 6 inhibitor’ (CDK4/6i) such as palbociclib, ribociclib or abemaciclib, given as a pill to be swallowed, plus the ER blocker fulvestrant, which is given as regular injections. There is a need for better hormonal therapies that can be given as a pill.

      A new ER blocker called giredestrant is given as a pill and may work better than fulvestrant, particularly against tumours with mutated ERs. Giredestrant is an investigational drug, which means health authorities have not approved it for treating ER-positive breast cancer.

      This study aims to compare the effects, good or bad, of giredestrant versus fulvestrant (both given with a CDK4/6i) in people with ER-positive, HER2-negative breast cancer that is resistant to prior adjuvant hormone therapy.

      2. How does the pionERA BC study work?

      This study is recruiting people with ER-positive, HER2-negative breast cancer that is resistant to a previous adjuvant hormone therapy. People can take part if their cancer has or has not got mutated ERs, and has grown (advanced) or spread to other parts of the body (metastatic).

      People who take part in this study (participants) will be given the study treatment giredestrant or fulvestrant, both combined with a CDK4/6i (palbociclib, ribociclib or abemaciclib) until their cancer gets worse or they have unacceptable side effects. The study doctor will see them regularly. These hospital visits will include checks to see how the participants respond to the treatment, including any side effects they may have. Total time of participation in the study is expected to be, on average, about 3–5 years, depending on how well treatment works. Participants can stop study treatment and leave the study at any time.

      3. What are the main results measured in the pionERA BC study?

      The main results measured to assess if the drug has worked (the main study endpoint) is the amount of time between the start of the study treatment and the progression of a participants’ disease (progression-free survival).

      The other key results include:

      • How long participants live (overall survival)
      • The number of participants whose tumours shrink with study treatment (overall response rate) and the amount of time this lasts if cancer worsens (duration of response)
      • The number of participants whose tumours shrink or stay the same for at least 6 months with study treatment (clinical benefit rate)
      • The amount of time between the start of the study treatment and:
        • participants needing chemotherapy (time to chemotherapy)
        • participants’ pain, quality of life and/or ability to perform daily activities getting considerably worse (time to confirmed deterioration)
      • The number and seriousness of side effects (safety and tolerability)

      4. Who can take part in this study?

      People can take part in this study if they have advanced or metastatic ER-positive, HER2-negative breast cancer that relapsed during or up to 1 year after adjuvant hormone therapy and are about to start their first treatment for advanced breast cancer.

      People may not be able to take part in this study if they have previously received certain anti-cancer treatments, have certain other medical conditions such as heart or liver disease or certain infections, are pregnant or breastfeeding, or are intending to have a baby.

      5. What treatment will participants be given in this study?

      Everyone who joins this study will be split into 2 groups randomly (like flipping a coin) and given either giredestrant as a pill once a day OR fulvestrant as an injection twice during the first month and then every 4 weeks. All participants will also receive a CDK4/6i treatment as a pill (palbociclib or ribociclib once a day on Days 1−21, or abemaciclib twice a day on Days 1–28 of each 28-day cycle). Participants will have an equal chance of being placed in either group. Women who have not completed menopause and men will also be given an ‘LHRH-agonist therapy’ to lower their natural levels of oestrogen, which is a standard-of-care treatment. This is an open-label study, which means everyone involved, including the participant and the study doctor, will know the study treatment the participant has been given.

      6. Are there any risks or benefits in taking part in this study?

      The safety or effectiveness of the study treatment or use may not be fully known at the time of the study. Most studies involve some risks to the participant. However, it may not be greater than the risks related to routine medical care or the natural progression of the health condition. People who would like to participate will be told about any risks and benefits of taking part in the study, as well as any additional procedures, tests, or assessments they will be asked to undergo. All of these will be described in an informed consent document (a document that provides people with the information they need to decide to volunteer for the study).

      Risks associated with the clinical study drugs

      Participants may have side effects (an unwanted effect of a drug or medical treatment) from the drugs used in this study. Side effects can be mild to severe, even life-threatening, and vary from person to person. Participants will be closely monitored during the study; safety assessments will be performed regularly. Participants will be told about the known side effects of giredestrant, fulvestrant, palbociclib, ribociclib and abemaciclib and possible side effects based on human and laboratory studies or knowledge of similar drugs. Giredestrant, palbociclib, ribociclib and abemaciclib will be given as an oral pill (by mouth); fulvestrant will be given by intramuscular injection (involves inserting a needle into the muscle of the buttocks). Participants will be told about any known side effects of taking pills and intramuscular injections.

      Potential benefits associated with the study

      Participants' health may or may not improve from participation in the clinical study. Still, the information collected may help other people with similar medical conditions in the future.

      Trial Summary

      This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT06065748,CO44657,2022-502980-39-00 Trial Identifier
      Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx) Treatments
      Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Condition
      Official Title

      A phase III randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with estrogen receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent
      • Documented estrogen receptor-positive (ER+), HER2-negative (HER2-) tumor assessed locally on the most recent tumor biopsy (or archived tumor sample)
      • Confirmed ESR1 mutation status (ESR1m vs. ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing
      • Resistance to prior adjuvant endocrine therapy (ET). Prior use of neo/adjuvant CDK4/6i is allowed.
      • No prior systemic anti-cancer therapy for advanced disease
      • Measurable disease as defined per RECIST v.1.1 or non-measurable bone-only disease
      • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1
      • For pre/perimenopausal women and for men: treatment with LHRH agonist therapy (as per local guidelines) for the duration of study treatment is required
      Exclusion Criteria
      • Prior systemic therapy (e.g., prior chemotherapy, immunotherapy, or biologic therapy) for locally advanced unresectable or metastatic breast cancer
      • Prior treatment with another SERD (e.g., fulvestrant, oral SERDs) or novel ER-targeting agents
      • Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
      • Active cardiac disease or history of cardiac dysfunction
      • Clinically significant history of liver disease

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now